タナカ　ジユンジ   TANAKA Junji   田中　淳司    所属   その他 その他    職種   非常勤嘱託
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Role of alternative donor allogeneic hematopoietic stem cell transplantation in patients with intermediate- or poor-risk acute myeloid leukemia in first complete remission.
掲載誌名	正式名：Bone marrow transplantation 略　 称：Bone Marrow Transplant ISSNコード：14765365/02683369
掲載区分	国外
巻・号・頁	pp.in press
著者・共著者	Yano Shingo†, Yokoyama Hiroki, Yanada Masamitsu, Mori Jinichi, Aoki Jun, Ohashi Kazuteru, Kanomori Heiwa, Ozawa Yuichiro, Sawa Masashi, Nakamae Hiroshisa, Eto Tetsuya, Ohta Shuichi, Tanaka Junji, Ichinohe Tatsuo, Atsuta Yoshiko, Takami Akiyoshi
発行年月	2019/05
概要	Allogeneic hematopoietic stem cell transplantation (HCT) offers the most effective prevention of relapse and has significant overall survival (OS) benefits for patients with acute myeloid leukemia (AML) in first complete remission (CR1). We conducted a retrospective analysis of a cohort of patients with intermediate- or poor-risk AML. The purpose of the present study was to investigate the role of alternative donors for AML in CR1. We analyzed 1561 patients who underwent HCT from an HLA-matched related donor (MRD), HLA 8/8-matched unrelated donor (MUD), or umbilical cord blood (UCB). The results of a multivariate analysis showed that HCT from UCB (HR = 1.28, 95% CI: 1.07-1.52), age ≥50 years (HR = 1.36, 95% CI: 1.14-1.62), male (HR = 1.42, 95% CI: 1.21-1.66), PS > 1 (HR = 1.68, 95% CI: 1.17-2.42), and poor-risk cytogenetics (HR = 1.53, 95% CI: 1.29-1.81) had an inferior prognostic impact on OS. We conclude that an MUD is the best alternative to an HLA identical MRD for patients with AML in CR1. UCB is an alternative option if neither MRD nor MUD are available, or when patients need to receive urgent HCT for poor-risk AML in CR1.
DOI	10.1038/s41409-019-0571-8
PMID	31152148